Effect of Cholesterol and Different Solvents on Particle Size, Zeta Potential and Drug Release of Eucalyptus Oil Phytosome

Background: Herbal extracts show poor absorption and bioavailability but their complex with phospholipids i.e., phytosome improves this major problem. Aim: The aim of research was to examine the effect of cholesterol and different organic solvents on particle size and zeta potential of eucalyptus oil phytosome. Materials and Methods: Totally six batches of phytosomes were prepared using three solvents chloroform, dichloromethane, acetone, with and without addition of cholesterol. Phytosome were evaluated for yield, FTIR, partial size and zeta potential, drug entrapment and drug release, drug release kinetics and stability studies. Results: The yield, density refractive index and maximum absorbance (λmax) of eucalyptus oil was found to be 1.65±0.74%, 0.9928 g/cm³ (24.2°C), 1.3613(24.6°C), and 297.733 nm respectively. There was no drug excipient interaction. The yield varied from 85.14±0.74 to 87.14±0.74%, particle size varied from 71.76±0.63 to 197.36±0.53 nm, zeta potential varied from 15.3±0.27 to-28.2±0.26 mV and entrapment efficiency varied from 57.45±0.35 to 67.34±0.52 respectively. The in vitro drug release varied from 87.26±0.63 to 71.35±0.63% up to 300 min (5 hr) and batch-A was selected as best formulation that showed Peppas Korsmeyer as the best fit model with R2 value 0.9422 and mechanism of drug release was Fickian Diffusion (Higuchi Matrix). The stability studies showed 99.14±0.25 to 99.55±0.52% drug content on 28th day. Conclusion: The particle size of phytosomes was increased on addition of cholesterol. The acetone showed the smallest particle size and chloroform showed the biggest particle size that indicated that molecule diameter and molecular weight affects the solubility and assembly of phospholipid/ cholesterol in solvent in order to prepare particulate drug delivery syste

Innovations In Formulation And Evaluation Of Oral Fast Dissolving Film

The most popular and convenient route for the drug administration is oral route with some merits, demerits, and limitations with some paediatric and geriatrics patients as they face difficulty to take solid dosage forms like capsules or compressed tablets that results in improper dosing due to vomit or removal of drug from buccal cavity. Oral fast dissolving films are a good alternate to overcome these difficulties and to deliver the drugs with any these age groups. Fast dissolving oral films are capable of delivering the drug locally and systemically by absorption through buccal mucosa, sublingual route, and oesophagus and finally form the stomach. Oral fast dissolving films offers a convenient way of dosing medication, not only for special groups of the population like paediatric, geriatric, confined to bed patients, patients with mental problems, but also to the general population. The present article review is focused on composition, preparation methods, evaluation and advancements of orally fast dissolving oral films

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019 : a systematic analysis for the Global Burden of Disease Study 2020, Release 1

Background Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dosespecific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in countryreported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings By 2019, global coverage of third-dose DTP (DTP3; 81.6% [95% uncertainty interval 80.4-82 .7]) more than doubled from levels estimated in 1980 (39.9% [37.5-42.1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38.5% [35.4-41.3] in 1980 to 83.6% [82.3-84.8] in 2019). Third- dose polio vaccine (Pol3) coverage also increased, from 42.6% (41.4-44.1) in 1980 to 79.8% (78.4-81.1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56.8 million (52.6-60. 9) to 14.5 million (13.4-15.9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. Interpretation After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1

10.1016/s0140-6736(21)00984-3The Lancet39810299503-52